Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19344588 | BRAND-NEW SKELETON 99MTC-FAPI DIAGNOSTIC PROBE AND USE THEREOF IN PREPARATION OF DRUG OR REAGENT FOR DIAGNOSING TUMORS | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19343371 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19340137 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | September 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19339250 | Intraoral Cleaning Tablet | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19326225 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | September 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19324663 | MARINE ORGANISM INFUSED EFFERVESCENT TABLET FOR PRODUCING ENHANCED SUSPENSIONS | September 2025 | January 2026 | Allow | 4 | 0 | 1 | Yes | No |
| 19319209 | AQUEOUS COMPOSITION | September 2025 | February 2026 | Allow | 5 | 1 | 0 | Yes | No |
| 19316708 | SELF-REGULATING PHOTO-CURABLE COOLING HYDROGEL AND PREPARATION METHOD AND APPLICATION THEREOF | September 2025 | January 2026 | Allow | 4 | 0 | 1 | Yes | No |
| 19311629 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | August 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19309669 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19307939 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19302265 | ALLERGEN DESENSITIZATION METHOD | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19302463 | SOLID DOSAGE FORMS OF ELAFIBRANOR | August 2025 | March 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19301647 | IMMEDIATE RELEASE MULTILAYER TABLET | August 2025 | December 2025 | Allow | 4 | 1 | 0 | No | No |
| 19300134 | DURABLE ANTI-FUNGAL AND ALGAE RESISTANT COATINGS | August 2025 | November 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19297675 | METHOD FOR WEED CONTROL IN LAWN OR TURF | August 2025 | March 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19278180 | LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATION | July 2025 | October 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19275155 | FORMULATIONS OF ANTI-INTERLEUKIN 1 RECEPTOR 1 ANTIBODIES | July 2025 | November 2025 | Allow | 4 | 1 | 0 | No | No |
| 19272053 | BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODS | July 2025 | January 2026 | Allow | 6 | 0 | 0 | No | No |
| 19268785 | INJECTABLE LEUCOVORIN FORMULATIONS AND METHODS OF PREPARING SAME | July 2025 | January 2026 | Allow | 6 | 1 | 1 | Yes | No |
| 19264750 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19263736 | METHOD OF TREATING CANCER USING CaV2O6/CaSiO3/g-C3N4 NANOCOMPOSITE | July 2025 | September 2025 | Allow | 3 | 0 | 0 | No | No |
| 19254167 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION | June 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19251149 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | June 2025 | September 2025 | Allow | 3 | 1 | 0 | No | No |
| 19247635 | Coralline Hydroxyapatite And Preparation Method Thereof | June 2025 | December 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19243333 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | June 2025 | March 2026 | Allow | 9 | 1 | 0 | Yes | No |
| 19238194 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | June 2025 | March 2026 | Allow | 9 | 2 | 0 | Yes | No |
| 19230961 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | June 2025 | December 2025 | Allow | 6 | 1 | 1 | No | No |
| 19224452 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | May 2025 | November 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 19222659 | ASSOCIATED FORMS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND LOCAL ANESTHETICS | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19220988 | DISPENSER AND METHOD OF USE THEREOF | May 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19216474 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | May 2025 | October 2025 | Allow | 5 | 1 | 1 | No | No |
| 19214778 | METHOD OF TREATING CANCER USING A ZrO2@CaSiO3@g-C3N4 NANOCOMPOSITE MATERIAL | May 2025 | July 2025 | Allow | 2 | 0 | 0 | No | No |
| 19214841 | CATIONIC LIPIDS AND PREPARATION METHOD THEREOF | May 2025 | January 2026 | Allow | 8 | 0 | 0 | No | No |
| 19210719 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | May 2025 | January 2026 | Allow | 8 | 2 | 0 | Yes | No |
| 19210389 | Herbicidal compositions comprising clethodim | May 2025 | December 2025 | Allow | 7 | 1 | 0 | No | No |
| 19210210 | Herbicidal compositions comprising acetochlor | May 2025 | December 2025 | Allow | 7 | 1 | 0 | No | No |
| 19209542 | CALCIUM OR MAGNESIUM CHLORIDE SALT-BASED COMPOSITION | May 2025 | August 2025 | Allow | 3 | 2 | 0 | Yes | No |
| 19209056 | STABLE PHARMACEUTICAL FORMULATIONS OF AMINO ACIDS, PEPTIDES OR PROTEINS | May 2025 | January 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 19208234 | CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS | May 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19206964 | COMPOSITION AND METHOD FOR TREATING HEARING LOSS | May 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19207162 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | May 2025 | December 2025 | Allow | 7 | 2 | 0 | No | No |
| 19205510 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | May 2025 | June 2025 | Allow | 1 | 0 | 0 | Yes | No |
| 19204534 | GENE DELIVERY SYSTEM AND APPLICATION THEREOF IN PREPARATION OF DRUGS FOR TREATMENT OF TUMORS | May 2025 | January 2026 | Allow | 8 | 1 | 1 | No | No |
| 19204235 | RADIOPHARMACEUTICAL COMPOSITIONS FOR LOW TOXICITY ACTINIUM IN TARGETED RADIONUCLIDE THERAPY | May 2025 | August 2025 | Allow | 3 | 0 | 1 | No | No |
| 19202501 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19194125 | ORGANIC NANOCOMPOSITE COATING FOR PHARMACEUTICAL APPLICATIONS AND A METHOD OF FABRICATION THEREOF | April 2025 | August 2025 | Allow | 3 | 0 | 1 | No | No |
| 19193039 | Herbicidal compositions comprising isoxaflutole | April 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19186092 | TREATMENT OF IMMUNOSUPPRESSED SUBJECTS | April 2025 | June 2025 | Allow | 2 | 1 | 0 | No | No |
| 18852937 | CATIONIC LIPID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | April 2025 | November 2025 | Allow | 14 | 2 | 0 | No | No |
| 19184830 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | April 2025 | July 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19183794 | NEW TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASES | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19182602 | Cosmetic Formulation | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19181843 | ATOMOXETINE HYDROCHLORIDE ORAL SUSPENSION AND USE THEREOF | April 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19182311 | ATOMOXETINE HYDROCHLORIDE ORAL SUSPENSION AND USE THEREOF | April 2025 | July 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19180813 | BIOORTHOGONAL COMPOSITIONS | April 2025 | December 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19178993 | NANOCARBON-IODINE CALCIUM ALGINATE MICROSPHERES AND PREPARATION METHOD AND APPLICATION THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19177144 | Lip Balm Containing Caffeine, Nicotine or Testosterone | April 2025 | December 2025 | Abandon | 8 | 2 | 0 | Yes | No |
| 19177269 | ORAL FORMULATION OF A THERAPEUTIC COMPOUND | April 2025 | October 2025 | Abandon | 7 | 1 | 0 | Yes | No |
| 19175378 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19175330 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | December 2025 | Allow | 8 | 1 | 0 | No | No |
| 19176038 | PREVENTION OF ACCUMULATED TOLERANCE TO STIMULANT MEDICATION FOR THE TREATMENT OF ADHD | April 2025 | January 2026 | Allow | 9 | 1 | 0 | Yes | No |
| 19173931 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19174154 | ENCAPSULATED RESVERATROL (RSV) NANOPARTICLES | April 2025 | January 2026 | Allow | 9 | 1 | 0 | No | No |
| 19174523 | ANTICANCER AGENTS COMPRISING A g-C3N4@CuO/MgAl2O4 NANOHYBRID | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19174583 | TAMPER RESISTANT DOSAGE FORMS | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19174612 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | April 2025 | August 2025 | Allow | 5 | 1 | 1 | No | No |
| 19172077 | Methods of administering safe colon cleansing compositions | April 2025 | December 2025 | Allow | 8 | 1 | 0 | No | No |
| 19172483 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | April 2025 | July 2025 | Allow | 3 | 0 | 0 | No | No |
| 19172351 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19170693 | Herbicidal compositions comprising topramezone | April 2025 | December 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19170092 | TRIPTOLIDE FORMULATIONS | April 2025 | January 2026 | Allow | 10 | 1 | 1 | No | No |
| 19169459 | BURDOCK SEED OIL-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19169843 | USE OF VARENICLINE FOR TREATING OCULAR CONDITIONS | April 2025 | February 2026 | Allow | 10 | 2 | 1 | No | No |
| 19098518 | EXTRACELLULAR MATRIX HYDROGEL MICROSPHERE, AND PREPARATION METHOD AND APPLICATION THEREOF | April 2025 | August 2025 | Allow | 5 | 0 | 1 | No | No |
| 19097284 | 1-NAPHTHALENYL AMINOETHYL SCHIFF BASE AND USE AS A DEATH LIGAND-1 INHIBITOR | April 2025 | August 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 19097443 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | April 2025 | September 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19097811 | INJECTABLE CARBOPLATIN FORMULATIONS | April 2025 | August 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19058112 | USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMOR | March 2025 | January 2026 | Abandon | 11 | 0 | 1 | No | No |
| 19095550 | CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME | March 2025 | September 2025 | Allow | 6 | 2 | 0 | No | No |
| 19094018 | TESTOSTERONE ENHANCING COMPOSITIONS AND METHODS | March 2025 | January 2026 | Allow | 10 | 2 | 0 | Yes | No |
| 19092739 | NOVEL RIVAROXABAN FORMULATION | March 2025 | October 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19088446 | ORGANIC DENTAL DEVICE AND METHOD OF PREPARATION THEREOF | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19080259 | METHOD OF INHIBITING CANCER CELL VIABILITY | March 2025 | June 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19078590 | Adhering Lozenge with High Amount of Sparsely Soluble Active Ingredient | March 2025 | October 2025 | Allow | 8 | 1 | 0 | No | No |
| 19077428 | TRADITIONAL CHINESE HERBAL PLANT COMPOSITION FOR IMPROVING SYMPTOMS OF LIVER CANCER PATIENTS AND COMPATIBILITY METHOD THEREOF | March 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19077685 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19077514 | COMPOSITION FOR HAIR PROTECTION OR HAIR STRENGTHENING | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19076524 | INHIBITION OF CANCER CELL VIABILITY | March 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19075007 | METHODS OF TREATING MIGRAINES WITH A COMBINATION OF A MELOXICAM AND A RIZATRIPTAN | March 2025 | November 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19075217 | MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19071625 | MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAME | March 2025 | January 2026 | Allow | 10 | 1 | 0 | No | No |
| 19069616 | AGRICULTURAL COMPOSITIONS COMPRISING REMODELED NITROGEN FIXING MICROBES | March 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19068391 | ORGANIC BIOMATERIAL FOR BONE AND JOINT REPLACEMENT | March 2025 | May 2025 | Allow | 2 | 0 | 0 | No | No |
| 19066754 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19065576 | METHODS OF TREATING GASTROINTESTINAL DISEASES AND DISORDERS | February 2025 | July 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19064093 | INHIBITION OF CANCER CELL VIABILITY | February 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 19064478 | Herbicidal compositions comprising mesotrione | February 2025 | October 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19062274 | INHIBITION OF CANCER CELL VIABILITY BY NANOCOMPOSITES OF GRAPHITIC C3N4, Fe2O3, AND MgAl2O4 | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19062757 | Methods of administering safe colon cleansing compositions | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1610.
With a 26.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1610 is part of Technology Center 1600. This group has examined 113,603 patent applications in our dataset, with an overall allowance rate of 46.8%. Applications typically reach final disposition in approximately 35 months.
Applications in Group 1610 receive an average of 2.36 office actions before reaching final disposition. The median prosecution time is 35 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.